IRVING, Texas, April 6 /PRNewswire-FirstCall/ -- Pursuant to NASDAQ Marketplace Rule 4350(b) (the "NASDAQ Rule") any Company, whose securities are listed on one of the NASDAQ stock exchanges, that receives a going concern audit opinion in one of its filings with the Securities and Exchange Commission is required to disseminate this information to the public. In compliance with this NASDAQ Rule, Carrington Laboratories, Inc. , today announced that it has received a going concern audit opinion for its financial statements dated as of December 31, 2006, and filed as part of its Annual Report on Form 10-K with the Securities and Exchange Commission. This going concern audit opinion was given because the Company has reported significant losses from operations and requires additional financing to fund future operations.
On February 22, 2007, the Company engaged Dawson James Securities, Inc. on an exclusive basis to develop and implement a strategy to ensure continued funding of the Company's operations and research and development efforts. The Company is optimistic that these efforts will be successful but there can be no guarantee.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com/ .
Carrington(R), Manapol(R), AloeCeuticals(R), Hydrapol(TM), GelSite(TM) and GelVac(TM) are trademarks, registered trademarks or service marks of Carrington Laboratories, Inc., in the United States and/or other countries. All other trademarks or service marks contained herein are the properties of their respective owners.
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-K, filed April 2, 2007.
